Valuation : Harrow, Inc.

Market Cap 1.4B 1.2B 1.13B 1.03B 1.94B 134B 1.95B 13.39B 5.23B 67.41B 5.25B 5.13B 224B P/E 2026 *
-348x
P/E 2027 * 16.6x
Enterprise Value 1.4B 1.2B 1.13B 1.03B 1.94B 134B 1.95B 13.39B 5.23B 67.41B 5.25B 5.13B 224B EV / Sales 2026 *
3.98x
EV / Sales 2027 * 2.62x
Free-Float
84.62%
Yield 2026 *
-
Yield 2027 * -
1 day-3.30%
1 week-8.99%
Current month-3.87%
1 month-5.21%
3 months+5.31%
6 months-31.21%
Current year-23.94%
1 week 37.07
Extreme 37.07
42.49
1 month 37.07
Extreme 37.07
43
Current year 28.54
Extreme 28.5401
54.85
1 year 28.54
Extreme 28.5401
54.85
3 years 7.6
Extreme 7.6
59.23
5 years 5.4
Extreme 5.4
59.23
10 years 1.35
Extreme 1.35
59.23
Manager TitleAgeSince
Chief Executive Officer 53 17/12/2011
President 43 21/08/2025
Compliance Officer - 01/10/2023
Director TitleAgeSince
Chairman 53 19/08/2021
Director/Board Member 57 31/03/2022
Director/Board Member 71 26/01/2024
Date Insider Type Main position Quantity % Market Cap.
14/08/26 Fiscal year

Chief Technology Officer

33,750 0.0905%
18/05/26 Buy

Director

1,000 0.0027%
18/05/26 Buy

Director

1,000 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
-3.30%-8.99%-4.41%+135.74% 1.4B
-0.13%-6.44%+60.47%+112.05% 1,047B
+0.85%-0.81%+52.77%+63.15% 646B
-1.03%-3.58%+22.87%+73.29% 451B
-1.46%-4.50%+37.43%+38.41% 355B
-0.72%-2.89%+21.86%+36.79% 291B
-1.19%-2.21%+1.35%+12.29% 252B
-1.05%-1.57%+51.40%+68.55% 234B
+0.08%-1.78%-17.64%-54.29% 203B
-2.14%-0.30%+29.42%+89.10% 181B
Average -1.02%-3.24%+25.55%+57.51% 366.07B
Weighted average by Cap. -0.48%-3.46%+38.64%+65.54%

Financials

2026 *2027 *
Net sales 351M 302M 283M 259M 487M 33.52B 489M 3.36B 1.31B 16.92B 1.32B 1.29B 56.1B 533M 459M 430M 393M 740M 50.9B 742M 5.1B 1.99B 25.69B 2B 1.96B 85.2B
Net income -3.92M -3.38M -3.17M -2.89M -5.45M -375M -5.46M -37.58M -14.66M -189M -14.72M -14.4M -627M 89.19M 76.85M 72.06M 65.78M 124M 8.52B 124M 855M 334M 4.3B 335M 328M 14.27B
Net Debt - -
Logo Harrow, Inc.
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Employees
373
Date Price Change Volume
28/08/26 $37.27 -3.30% 401,077
27/08/26 $38.54 -2.01% 442,670
26/08/26 $39.33 -4.84% 566,988
25/08/26 $41.33 +3.84% 472,368
24/08/26 $39.80 -2.81% 419,014
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
37.27USD
Average target price
67.50USD
Spread / Average Target
+81.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HROW Stock